Elan Corporation, plc today announced that Dr. Andrew von Eschenbach and
Mr. Hans Peter Hasler have become non-executive members of Elan's board
of directors and Mr. Shane Cooke has retired as an executive director.
Elan's Chairman, Robert Ingram commented "We are pleased to welcome Dr.
von Eschenbach and Mr. Hasler to the board of directors of Elan. Both
individuals possess exceptional professional backgrounds, the highest
degree of integrity and strength in character. Their joining our
existing high quality board will add to the depth and breadth of our
strategic discussions. We are also thankful for the significant
contributions made by Mr. Cooke during his ten years of service as
Elan's Chief Financial Officer and five years as an executive board
member. We wish Shane and Alkermes plc continued success."
Andrew von Eschenbach, MD (69) is currently the President
of Samaritan Health Initiatives Inc., a health care policy consultancy.
He previously served as Commissioner of the FDA from 2005-2009. Under
his leadership the FDA implemented: "Beyond Our Borders" - a systems
based "global" approach to regulation of food and medical products,
establishing for the first time a permanent FDA presence in 16 foreign
locations; and accelerated the Critical Path Initiative designed to
modernize the sciences through which the FDA regulated products are
developed, evaluated and manufactured.
Prior to being the Commissioner of the FDA, Dr. von Eschenbach served as
the Director of the National Cancer Institute (NCI) from 2002-2006. As
part of the National Institutes of Health and the Department of Health
and Human Services, NCI's main responsibilities include overseeing the
world's largest cancer research budget (~ $5 billion) by coordinating
the National Cancer Program which conducts and supports research,
training, health information dissemination and other programs with
respect to the cause, diagnosis, prevention and treatment of cancer,
rehabilitation from cancer, and the continuing care of cancer patients
and their families.
Dr. von Eschenbach held a number of leadership roles at the University
of Texas' M.D. Anderson Cancer Center from 1976-2002. He was educated at
St. Joseph's University, Philadelphia and received his M.D. from
Georgetown University, Washington D.C. His current responsibilities
include serving on the boards of Histosonics Inc., Viamet
Pharmaceuticals, Focused Ultrasound Surgery Foundation, and National
Comprehensive Cancer Centers Network Foundation. He also serves on the
advisory boards of Chugai Pharmaceutical International Advisory Council,
GE Heathymagination Advisory Boards and on the Scientific Advisory
Boards of Arrowhead Research Corporation and Johnson & Johnson/Corporate
Office of Science & Technology External Scientific Advisory Board and is
Senior Fellow at the Milken Institute and is a Senior Advisor to PWC
Mr. Hans Peter Hasler (55) is currently the Chairman of
HBM Bioventures AG and principal of HPH Management GmbH. Previously, Mr.
Hasler served with Biogen Idec in a number of key executive leadership
roles from 2001-2009. Prior to his departure from Biogen Idec, Mr.
Hasler served as its Chief Operating Officer responsible for all
commercial operations, business development, medical affairs and Biogen
International representing total revenues of $4.1 billion with 1,500
employees. During his tenure he served as Head of Global
Neurology/Cardiovascular business and head of International business
overseeing the launch of Tysabri in Europe and the management of Avonex.
Prior to joining Biogen Idec, Mr. Hasler served in a number of global
senior positions with Wyeth Pharmaceuticals and Abbott AG. He currently
serves as vice chairman of Acino Pharma AG, Director of Celltrion, Inc,
Seoul and Director of Ferring Holdings, Lausanne. He is a member of the
advisory board of EvaluScience, ETH, Zurich and is an advisor to Temasek
(Private) Ltd., Singapore.
Mr. Shane Cooke was the Chief Financial Officer for Elan
from July 2001 until May 2011 and had served as executive director since
2005. Prior to joining Elan, Mr. Cooke was Chief Executive Officer of
Pembroke Capital Limited. Following the completion of the merger between
Alkermes, Inc. and Elan Drug Technologies, Mr. Cooke will join the newly
formed Alkermes, plc as its President.
About Elan Corporation, plc
Elan Corporation, plc (NYSE:
ELN) is a neuroscience-based biotechnology company committed to making a
difference in the lives of patients and their families by dedicating
itself to bringing innovations in science to fill significant unmet
medical needs that continue to exist around the world. Elan shares trade
on the New York and Irish Stock Exchanges. For additional information
about the Company, please visit www.elan.com
Source: Elan Corporation, plc
Elan Corporation, plc